| Objective1.To investigate the clinical effect of apatinib combined with S-1 and decoction of Yiguanjian and Liujunzi on advanced gastric adenocarcinoma with qi-yin deficiency type;2.To investigate the adverse reactions in the antitumor treatment of apatinib combined with S-1,and the function of decoction of Yiguanjian and Liujunzi.Method Choose between January 2016 and January 2020 in the second affiliated hospital of anhui medical university and Lujiang County Hospital of traditional hinese Medicine,during the cultivated hospital oncology hospital or clinic patients,85 patients and are included in the standard,according to enter this order in the study of coding,an odd number into the treatment group,even for the control group,to the deadline for this study,treatment group 43 cases,control group included in 42 cases,according to the standard,fall off in 3 cases fall off(2 cases of treatment group and control group 1case),the treatment group and the control group(n = 41)in the end.Both the treatment group and the control group were given "apatinib +S-1" antitumor therapy.Changes in tumor markers(CEA,Ca125,Ca199),tumor efficacy evaluation,a variety of common adverse reactions,TCM syndrome score,and KPS score were compared between the two groups.Results1.Changes of CEA: comparison of CEA between the two groups before treatment,between the two groups after treatment,and between the two groups after treatment,there was no statistically significant difference after the t-test of the two independent samples(P >0.05).Comparison of CEA between the two groups before and after 4courses of treatment,the differences were statistically significant(P <0.05).2.Changes of CA125: comparison of CA125 between the two groups before treatment,in the second course of treatment and in the fourth course of treatment showed nostatistically significant difference by t test of two independent samples(P >0.05).Compared with CA125 in the two groups before and after 4 courses of treatment,the difference was statistically significant(P <0.05).3.Changes of CA199: CA199 was compared between the two groups before treatment,the two treatment courses,and the four treatment courses.By t test of two independent samples,the difference was not statistically significant(P >0.05).CA199 in the two groups before and after the fourth course of treatment showed statistically significant differences(P <0.05).4.Short-term evaluation of tumor efficacy: DCR of the treatment group and the control group were 78.04% and 68.29%,respectively.Wilcoxon test showed no statistically significant difference between the two groups in tumor efficacy evaluation,but DCR of the treatment group was higher than that of the control group.5.Adverse reactions of the blood system: the reduction of white blood cells,platelets and hemoglobin in the two groups was compared,and the Wilcoxon test showed statistically significant differences(P <0.05).6.The incidence of nausea,vomiting and diarrhea in the treatment group and the control group were compared.Wilcoxon test showed statistically significant differences(P <0.05).7.Anorexia,fatigue and stomatitis: Wilcoxon test showed statistically significant differences between the two groups in the comparison of anorexia,fatigue and stomatitis(P <0.05).8.Hypertension: the incidence of hypertension in the treatment group and the control group were 26.82% and 48.78%,respectively.Wilcoxon test showed statistically significant differences(P<0.05).9.Proteinuria: the incidence of proteinuria in the treatment group and the control group were 36.50% and 46.34%,respectively.Wilcoxon test showed no statistically significant difference(P>0.05).10.Transaminase and creatinine: Wilcoxon test showed no statistically significant difference in the changes of transaminase and creatinine between the treatment group and the control group(P> 0.05).11.Hand-foot syndrome: the incidence of hand-foot syndrome in the treatment group and the control group were 29.26% and 36.58%,respectively.Wilcoxon test showed no statistically significant difference(P>0.05).12.KPS score: Wilcoxon test showed a statistically significant difference in KPS scores between the two groups(P<0.05).13.Qi and Yin deficiency syndrome of TCM syndrome integral: treatment group(qi and Yin deficiency syndrome of TCM syndrome score before treatment,treatment of 4process changes within the group by two independent samples t test,the difference was statistically significant(P < 0.05),the control group before,4 routine treatment group within the change of TCM syndrome integral,the two independent samples t test,there was no statistically significant difference(P > 0.05),the level of TCM syndrome score between the two groups was statistically significant(P<0.05)by t test of two independent samples.Conclusion1.Apatinib combined with S-1 and consistent decoction of Yiguanjian and Liujunzi can be used to treat advanced gastric adenocarcinoma with deficiency of qi and Yin,which can play a certain anti-tumor effect and improve the disease remission rate.2.Yiguanjian and Liujunzi decoction can alleviate some of the adverse reactions in the anti-tumor treatment of apatinib combined with S-1,improve the quality of life of patients,and provide a basis for the clinical treatment of anti-vascular targeting combined with chemotherapy with traditional Chinese medicine. |
PDF Full Text Request